BMS Expands Texas Biotech with $400M+ & 300 New Jobs
HOUSTON, Texas — Pharmaceutical giant Bristol Myers Squibb (BMS) announced a significant expansion of its manufacturing footprint in Harris County on February 28, 2024, committing more than $400 million to grow its operations within the Houston Innovation Park.
The investment marks a major milestone for Texas’s rapidly evolving biotechnology sector. BMS plans to construct a new facility at its existing campus, which currently spans 1.1 million square feet. The project is expected to create 300 new, high-paying jobs over the next three years, focusing on roles within biologics, cell therapy, and other advanced manufacturing disciplines.
Governor Greg Abbott lauded the move as a validation of the state’s economic strategy. In a statement released following the announcement, Abbott attributed the company's decision to Texas’s unrivaled business climate, a robust life sciences ecosystem, and a highly skilled workforce that continues to draw global investment.
BMS, which already employs more than 500 people in the state, views the expansion as a strategic necessity to support its global supply chain. Randy Cox, Senior Vice President of Manufacturing and Global Engineering at Bristol Myers Squibb, noted that Houston’s unique combination of infrastructure and access to specialized talent made it the ideal location for scaling their cell therapy network.
The expansion is the latest in a series of high-profile investments that have solidified the Houston region’s status as a top-tier destination for pharmaceutical production. Industry analysts often refer to the region as the Medical Center of the South, a title bolstered by the concentration of research institutions and manufacturing capabilities located in and around the Texas Medical Center.
This development follows a broader trend of "reshoring" in the pharmaceutical industry, as global manufacturers seek to tighten supply chains by building production facilities closer to their primary markets. For Houston, the presence of BMS serves as a cornerstone for the city’s ongoing efforts to diversify its economy beyond traditional energy sectors.
The new facility will focus on the development and production of complex therapies, which are becoming increasingly central to modern oncology and immunology treatments. As the company begins the construction phase, officials anticipate that the project will also stimulate growth among regional suppliers and service providers that support the life sciences sector.
For those interested in the ongoing growth of the state's biotechnology industry, updates on local economic development projects are available through the Office of the Governor at gov.texas.gov and the Greater Houston Partnership at www.houston.org. Further information regarding employment opportunities at the expanded campus will be posted through the BMS careers portal at bms.com/careers.